Evidence map›Paper›PMID 40650185›Full record

ArticleInternational journal of molecular sciences2025

Hypoxic Status in COPD and ARDS Patients: Impact on Lipid Signature.

Camillo Morano, Aldijana Sadikovic, Michele Dei Cas, Rocco Francesco Rinaldo, Lorena Duca, Federico Maria Rubino, Michele Mondoni, Davide Chiumello, Sara Ottolenghi, Michele Samaja and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Mechanisms Underlying Altitude-Induced and Group 3 Pulmonary Hypertension.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Camillo MoranoClinical Biochemistry and Mass Spectrometry Unit, Department of Health Sciences, Università degli Studi di Milano, 20145 Milan, Italy.ORCID 0000-0003-0352-2819
Aldijana SadikovicClinical Biochemistry and Mass Spectrometry Unit, Department of Health Sciences, Università degli Studi di Milano, 20145 Milan, Italy.ORCID 0009-0009-9476-8208
Michele Dei CasClinical Biochemistry and Mass Spectrometry Unit, Department of Health Sciences, Università degli Studi di Milano, 20145 Milan, Italy.ORCID 0000-0001-7359-8558
Rocco Francesco RinaldoRespiratory Diseases Unit, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, Università degli Studi di Torino, 10124 Turin, Italy.ORCID 0000-0003-3999-5298
Lorena DucaUnit of Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0002-2008-3187
Federico Maria RubinoClinical Biochemistry and Mass Spectrometry Unit, Department of Health Sciences, Università degli Studi di Milano, 20145 Milan, Italy.ORCID 0000-0001-9620-1883
Michele MondoniRespiratory Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, Università degli Studi di Milano, 20145 Milan, Italy.
Davide ChiumelloComplex Structure of Anaesthesia and Intensive Care, Department of Health Sciences, ASST Santi Paolo e Carlo, Università degli Studi di Milano, 20145 Milan, Italy.
Sara OttolenghiDepartment of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, Italy.ORCID 0000-0003-2988-0593
Michele SamajaClinical Biochemistry and Mass Spectrometry Unit, Department of Health Sciences, Università degli Studi di Milano, 20145 Milan, Italy.ORCID 0000-0002-0705-340X
Rita ParoniClinical Biochemistry and Mass Spectrometry Unit, Department of Health Sciences, Università degli Studi di Milano, 20145 Milan, Italy.ORCID 0000-0002-3186-8860

Funding

Ministero dell'università e della ricerca G53D23001470006
6 · The paper itself

Abstract

In patients with respiratory diseases, a panel of markers is often used to assess disease severity and progression. Here we test whether the serum lipid signature may surge as a reliable alternative marker to monitor systemic hypoxia, a frequent unfavourable outcome in acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary diseases (COPD). We recruited 9 healthy controls, 10 COPD patients, and 10 ARDS patients. Various markers related to inflammation, redox imbalance, and iron handling were measured alongside lipid profiles obtained through untargeted lipidomic analysis. The results show that serum lipids were moderately lower in COPD patients and significantly reduced in ARDS patients compared to the controls. Six lipid classes (cholesteryl esters, coenzyme Q, phosphatidylinositol, sterols, hexosylceramides, and phosphatidylethanolamine) exhibited significant changes (ANOVA

Indexed as

HypoxiaLipidsPulmonary Disease, Chronic ObstructiveRespiratory Distress SyndromeAgedBiomarkersCase-Control StudiesFemaleHumansLipid MetabolismLipidomicsMaleMiddle AgedSeverity of Illness IndexBiomarkersLipidsacute hypoxiaacute respiratory distress syndromechronic hypoxiachronic obstructive pulmonary diseasemass spectrometryplasma biomarkersplasma lipidome

Identifiers

PMID40650185
PMCPMC12249815

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.